Does Diet Drug Meridia Contribute to Increased Heart Attack, Stroke Risk?

  • By Sean McDonnell on September, 03 2010
  • 0 comments

Abbott Lab’s popular diet drug Meridia (sibutramine) may soon be off the U.S. market after a clinical study of nearly 10,000 patients showed that use of the drug increased the risk of heart attack or stroke in patients with underlying heart disease, and did little to contribute to weight loss.

As reported in the Sept. 2, 2010, issue of The New England Journal of Medicine, the study involved about 10,700 overweight or obese people 55 or older who had heart disease, diabetes or both and were treated for about 3½ years. Overall, 11.4 percent of those on the diet pill had a heart attack, stroke or died of a heart-related cause, compared with 10 percent of those taking a placebo. Ironically, the study was financed by Meridia’s maker, Abbott Laboratories. To see the study article, click here.

In a strongly worded editorial, the Journal’s editors wrote that Meridia should be removed from the market, calling it “another flawed diet pill.” They continued: “It is difficult to discern a credible rationale for keeping this medication on the market.”

Meridia has already been banned in Europe. Later in September, the U.S. Food and Drug Administration will meet to determine whether it should take action on Meridia sales in the United States.

Meridia was approved in the U.S. market in 1997 – the same year the popular diet drug combo fen-phen was pulled from the market after being linked to heart valve problems. According to Abbott, Meridia’s global sales in 2009 were about $300 million.

Question for comment: Have you or someone you know ever taken a prescription diet drug such as Meridia? Or do you have another comment?